abbvie has been a terrific performer. stock is up more than 83% over the past 12 months but in the past two days, the stocks plunged from 122 to 112 bingo, that is the dip i have been looking for the company reported a stunning quarter sent the stock surging from $128 to 123 this pull back could be heavenly if it goes back four more points you will be getting the latest quarter for free for those of you who don't know, abbvie makes a host of major drugs. including the best selling drugs in the entire year r rummira. the company expects this one drug to do 21 billion in sales and that isn't the most exciting start of the story four cents earnings beat up 14% year after year they went from midpoint of 647 up to $7.38. fabulous sales forecast. that translated into 32% earning growth the stocks going down, look it did rally up 14% in the wake of the number this is not some cyclical smokestack play that is expected to raise numbers when economy is booming. pharma outfits almost never pull extra dollar per share a lot of it com

abbvie's quarter is boosting gilead because of hepatitis c drugs, a 32% market share. abrams calling it a positive market share all this leading biotech to get seriously close to its 2015 high here's where the warnings start to come in industry publications pointing out some of the activity in the space is causing investors to, quote, worry the sector is taking a turn for the absurd and josh schumer points out the state of theion address next week would throw cold water on the group in the milled of earnings season. wednesday also brings reports from eli lily and vertex >> thank you meg dan here had called the ibb the best chart ever earlier this week on "fast money. how are you trading it. >> i was going to say on a relative basis i think it's constructive. we are also in a market that obviously for a couple of months now is seemingly making new all-time highs on a daily basis. what we have seen is rotations, out of some groups and into some others when you look at the pickup we have seen in biotech stocks in the last few months, we have seen that rotation the xbi, ha

abbvie says its effective tax rate will be 9%. analysts had been expecting 20%. >> jared holtz is telling me investors are keeping a closer eye on this for any similar commentary of tax benefits they are boosting gilead for their results for hepatitis "c" drugs. it says a 32% market share brian abrams calling this a positive indicator for market stabilization in terms of number of patients treated as well as pricing. all of this leading biotech to get seriously close to its 2015 high here is where the warnings start to come in damian is pointing out some of the activity in the space is causing investors to worry the sector is taking a turn for the absurd they point out the state of the union address next week. it could throw some cold water on the group in addition to pfizer and amgen reporting, wednesday will bring reports from eli lilly and v vertez >> dan had called it the best chart ever on ""fast money." >> i say on a relative basis it is very constructive. we are in a market that is seemingly making new all-time highs on a d

abbvie a big help their winner today and biogen trading higher after the price target was taken higheror this company on a strong earnings report. withly, let's rounded out the cryptocurrency space. #btv, the#btv -- g weekly gains and declines for bitcoin over two years, lots of movement, especially last year ,hen bitcoin climbed, climbed but now three down weeks in a row. today bitcoin is down on a report that the japanese a guest -- biggest-- tocoin trading closer $10,000 after an all-time high of $19,500 last year. i will join our technology analyst to talk about a drop down towards $1000. mark: returning to the economy. gdp faster than expected in the fourth quarter with growth last year slowing, the weakest pace in five years. here to discuss that and much chiefur our london bureau and european economist for bloomberg economics. we will put a wall in between you. let's start with you. the fourth quarter ,wow, the year as a whole, oh, dear. >> if we sat here two years ago and gdp would be here, we would not be celebrating, we would be miserable. it has to do with the brexit. contex

abbvie is up $13 i wouldn't hold your breath if you are waiting for that kind of thing from pfizer. pfizer is like a utility we also hear from mcdonald's ceo has turned this aging hulk around to the point where it is now doing three times the same-store sales as starbucks. i think value is one part of the story, but the other part, the bathrooms are clean. don't laugh. after closing resulted of amd sent the stocks surging more than 10% can it break through this level? you bet as long as dr. lisa sue the ceo tells a good story and i expect she will. earning super bowl goes into full throttle. i have to hope that the short-term crowd comes out in force and sells the stock. or on the loss of a trading commission against bombardier which happened today i say you might get a chance to buy it because honeywell, the conglomerate reported today and gave you aslight miss. that was a buying opportunity as honeywell surged higher. all of the industrials are up today. a lot of it is davos a lot of it is the president i am pretty convinced that the one area i was interested about in slowing pers

you yo guys >> thank you, dom chu in the newsroom speaking of the force, shares of cigna, anthem, abbviel down. is this the time to buy them >> i think now is the time i don't think you take your foot off the gas. it could take them a long time to get into the mix here and have competitive threats. >> i agree when the amazon/whole foods deal happened, that happened, done, they closed in three months or however long so you could immediately see the effects. here we are a ways off from seeing what -- >> they said they want to lower prices so every american family pays less for their groceries and they don't care about making the profit and that's what they're saying in this press release. >> not for profit, u.s. employees and hopefully the american people will pay less for health care. doesn't that cast this in a very different light? >> no, because -- that part is different because that it can't happen right away. whole foods happened right away, right? immediately they started lowering prices. >> we don't know how they're going to help these one million employees of theirs. but ultimatel

some relief for investors that the chip design flaw is not waiting into the forecast. , up 12.9%k at abbvie after beating and raising as well, and also talking about a 9% tax rate for 2018. starbucks, however, and colgate are lower on earnings disappointments. dropped for the fifth quarter in a row, but analysts are bullish on the possibility of china. investors not so much today. colby down 5.6 percent, missing both of the bottom line. -- results were colgate colgate down five .6%, missing both the bottom and top lines. the wallidday, and street journal did put out a report saying that steve wynn, the ceo, founder, and chairman hasindward -- wynn resorts exhibited a pattern of harassing women. investors are clearly not liking that report. a very pivotaly part of that company, that drop wiping out $18 billion from the value of that stock. thank you, abigail. let's check on the first word news this afternoon with mark crumpton. mark? mark: in davos, president trump told the world economic forum that america is "open for business." he says he has taken aim at bureaucrats and their regulations

. >> abbvie is dug maker. stuart: pick on those two, why are they biblically responsible?esting we're looking for biblically investing company. they are doing good with business, operating high degree of ethics and morales and giving back community. avoid tangling in anything anti-biblically. we're avoiding companies involved in abortion, pornography, human trafficking, things like that. problem with human trafficking and those sorts of things. but that is company pays very close tending to that issues. be a v. does not involve in the abortion industry. stuart: what do performance of your four funds compared to the s&p, are you beating them. >> we are beating them? stuart: consistently? >> consistently. stuart: by how much. >> today the s&p is down half a percent. we're down .21. stuart: over longer term, the s&p has done very well up, 20, 25%. are you up, 20, 25%. >> we are. stuart: you are? better than that? >> we are. stuart: turn it around, which companies if you want to name them, would i like to hear the names, would you specifically not invest in? >> microsoft. we t